DXC
DXC Technology Co
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeDXC reported Q1 FY2027 revenue of $3.0B (down 5.1% YoY) with EPS of $0.40 slightly missing estimates, while bookings grew 5% YoY suggesting some stabilization. Strategic AI partnerships with Anthropic and ElevenLabs position the company for longer-term transformation, but Wall Street consensus remains 'Reduce' with price targets cut through summer 2026, reflecting persistent investor skepticism about the turnaround trajectory.
Red flags
- •Organic revenue declined 6.7% in Q1 FY27; multi-quarter downtrend continues
- •EPS of $0.40 missed consensus estimate of $0.41
- •Bookings-to-bill ratio of 0.99x signals weak forward demand visibility
- •Nine analyst firms covering DXC now have consensus 'Reduce' rating with 2 'sell' calls
- •Price targets cut by Stifel (to $10.50), RBC (to $14.00), and Morgan Stanley reaffirmed at $12.00 vs. stock price of $10.83
- •Shareholders rejected expansion of Omnibus Incentive Plan at annual meeting, signaling governance/pay dissatisfaction
- •Stock trading 31% below 52-week high of $15.68 despite insider/institutional ownership increases
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Glenview Capital | SC 13G/A | −8.9M | 0.0% | +8.0% vs SPY +8.1% abs | 2026-08-14 | ↗ |
| Glenview Capital | SC 13G | NEW | 5.2% | — | 2026-03-27 | ↗ |